| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Anesthesiology, Chang Gung Memorial Hospital, Tao-Yuan, Taiwan.
Address correspondence to: Dr. Peter C.H. Chung, Department of Anesthesiology, Chang Gung Memorial Hospital, 5 Fu-Hsing Street, Kwei-Shan, Tao-Yuan, 333, Taiwan. Phone: +886-3-3281200, ext. 2389; Fax: +886-2-28737816; E-mail: steve226{at}ms23.hinet.net
| Abstract |
|---|
|
|
|---|
Clinical features: A 36-yr-old male underwent adrenectomy for pheochromocytoma. Midazolam 5 mg, fentanyl 100 µg and labetalol 20 mg were administrated intravenously for premedication upon arrival in the operating theatre. After induction of anesthesia with fentanyl, thiopental and atracurium, 30 mg iv labetalol was administered. The blood pressure gradually rose to 178/101 mmHg with mildly increased SVRI (1958 dn-sec-1m2cm5) and stable CI (3.8 Lmin-1m2 ). The blood pressure reached 247/150 mmHg after intubation with an increase in SVRI (3458 dn-sec-1m2cm5) and a decrease in CI (3.6 Lmin-1m2). The SVRI increased further to 4986 dn-sec-1m2cm5 and CI declined to 2.4 Lmin-1m2 after the administration of additional labetalol 20 mg. Sodium nitroprusside was administered and the blood pressure declined immediately to 108/72 mmHg, with a decreased SVRI (2526 dn-sec-1m2cm5) and stable CI (2.3 Lmin-1m2).
Conclusions: The elevated SVRI with low CI was considered to result from increased
-adrenergic activity secondary to ß-adrenergic blockade with labetalol. Clinicians should be aware of the possibility of a hypertensive crisis after iv labetalol. We suggest that labetalol should be replaced promptly with
-adrenergic blockers or other vasodilators when such a condition arises.
| Clinical features |
|---|
|
|
|---|
|
| Discussion |
|---|
|
|
|---|
Generally, during the treatment of hypertension, if ß-adrenergic receptors are blocked first, norepinephrine and epinephrine will produce unopposed -adrenergic stimulation. ß2-mediated vasodilation will not be able to offset 1 vasoconstriction, and peripheral vascular resistance will increase.1 Theoretically, without adequate -adrenergic blockade, ß-adrenergic blockade may result in high peripheral vascular resistance and hypertension. Therefore, weak -adrenergic blockade and strong ß-adrenergic blockade are not an ideal combination for an anti-hypertensive agent. However, labetalol is such an agent and has been used effectively for years as an anti-hypertensive agent without reports of high vascular resistance,25 even in patients with norepinephrine-secreting pheochromocytoma.6 But, as the use of continuous CO monitoring becomes more widespread, hemodynamic changes following the use of labetalol can be demonstrated more clearly. It can provide more accurate and reliable information on CO than the traditional devices,7 especially in a hemodynamic emergency such as during pheochromocytoma resection. With a coiled heater at the tip of the pulmonary artery catheter, CO can be estimated every ten seconds, and the average value of the last few CO measurements can be displayed, as can 30 min to 24 hr trends of CO.
In this case, the blood pressure increased while CO remained stable after administration of labetalol before intubation, and the blood pressure continued to increase despite a decrease in CO after increasing doses of labetalol after intubation. In our experience, the combination of fentanyl (5 µgkg-1), thiopental (5 mgkg-1), labetalol (0.51 mgkg-1), and isoflurane with an expired concentration between 1.2 and 1.5% provides adequate anesthesia for intubation. So, we concluded that the increase in blood pressure was related mainly to the administration of labetalol.
The aim of this report is to remind clinicians of the possibility of SVRI elevation and hypertensive crisis after iv labetalol. We suggest that labetalol should be replaced promptly with -adrenergic blockers or other vasodilators when such a condition arises, in order to prevent the possible cardiac and pulmonary complications induced by further ß-blockade.
Revision received November 5, 2001. Accepted for publication September 5, 2001.
| References |
|---|
|
|
|---|
2 Farmer JB, Kennedy I, Levy GP, Marshall RJ. Pharmacology of AH 5158; a drug which blocks both - and ß-adrenoceptors. Br J Pharmacol 1972; 45: 66075.[Medline]
3 Bailey RR. Labetalol in the treatment of a patient with phaeochromocytoma: a case report. Br J Clin Pharmacol 1979; 8: 141S2S.[Medline]
4 Kaufman L. Use of labetalol during hypotensive anaesthesia and in the management of phaeochromocytoma. Br J Clin Pharmacol 1979; 8: 229S32S.[Medline]
5 Chung PCH, Sum DCW, Wu RSC. High dose intravenous labetalol for the resection of metastatic pheochromocytoma. Acta Anaesthesiol Sin 1996; 34: 2358.[Medline]
6 Chung PCH, Sum DCW. Preliminary experience of using fixed dose of intravenous labetalol in surgical resection of pheochromocytoma. Acta Anaesthesiol Sin 1993; 31: 2116.
7 Boldt J, Menges T, Wollbruck M, Hammermann H, Hempelmann G. Is continuous cardiac output measurement using thermodilution reliable in the critically ill patient? Crit Care Med 1994; 22: 19138.[Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |